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Sir,
We are grateful to Cucchetti et al for their interest in
our work, and pleased that they are in strong agreement, in
principle, with our suggestion that transplantation may be the
most appropriate therapy for HCC patients classified as ALBI
grade-2 (Toyoda et al, 2016). Furthermore, we agree that it
would be of interest to compare the utility of ALBI with the
current standard for transplant prioritisation, the Model for
End-stage Liver Disease score. Indeed, we are currently
undertaking such a comparison and hope to publish this work
shortly.
However, we also agree with Cuchetti et al that we should have
been more cautious in suggesting ablation as an alternative option to
resection for ALBI grade-2 patients. Indeed, our data does not directly
support this contention.
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